News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
184,983 Results
Type
Article (6416)
Company Profile (6)
Press Release (178561)
Multimedia
Podcasts (8)
Webinars (1)
Section
Business (50925)
Career Advice (76)
Deals (9007)
Drug Delivery (6)
Drug Development (29125)
Employer Resources (10)
FDA (4648)
Job Trends (4035)
News (92289)
Policy (6801)
Tag
Academia (544)
Accelerated approval (3)
Adcomms (4)
Allergies (32)
Alliances (7529)
ALS (47)
Alzheimer's disease (580)
Antibody-drug conjugate (ADC) (62)
Approvals (4730)
Artificial intelligence (105)
Autoimmune disease (15)
Automation (8)
Bankruptcy (71)
Best Places to Work (4017)
BIOSECURE Act (3)
Biosimilars (32)
Biotechnology (6)
Bladder cancer (59)
Brain cancer (13)
Breast cancer (164)
Cancer (1285)
Cardiovascular disease (84)
Career advice (63)
Career pathing (1)
CAR-T (45)
Cell therapy (164)
Cervical cancer (14)
Clinical research (25399)
Collaboration (372)
Compensation (186)
Complete response letters (1)
COVID-19 (467)
CRISPR (11)
C-suite (82)
Cystic fibrosis (45)
Data (1273)
Depression (11)
Diabetes (83)
Diagnostics (1618)
Digital health (7)
Diversity, equity & inclusion (2)
Drug discovery (36)
Drug pricing (9)
Drug shortages (2)
Duchenne muscular dystrophy (46)
Earnings (34096)
Editorial (11)
Employer resources (8)
Events (46166)
Executive appointments (313)
FDA (5224)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (2)
Frontotemporal dementia (2)
Funding (317)
Gene editing (30)
Generative AI (3)
Gene therapy (111)
GLP-1 (175)
Government (911)
Grass and pollen (3)
Guidances (26)
Healthcare (5092)
Huntington's disease (8)
IgA nephropathy (13)
Immunology and inflammation (47)
Indications (15)
Infectious disease (518)
Inflammatory bowel disease (60)
Inflation Reduction Act (2)
Influenza (15)
Intellectual property (34)
Interviews (15)
IPO (5444)
IRA (2)
Job creations (352)
Job search strategy (54)
Kidney cancer (4)
Labor market (1)
Layoffs (49)
Leadership (1)
Legal (1173)
Liver cancer (38)
Lung cancer (222)
Lymphoma (85)
Machine learning (2)
Management (4)
Manufacturing (85)
MASH (27)
Medical device (3409)
Medtech (3409)
Mergers & acquisitions (3858)
Metabolic disorders (205)
Multiple sclerosis (43)
NASH (13)
Neurodegenerative disease (35)
Neuropsychiatric disorders (7)
Neuroscience (831)
NextGen: Class of 2025 (1312)
Non-profit (910)
Now hiring (1)
Obesity (93)
Opinion (26)
Ovarian cancer (32)
Pain (35)
Pancreatic cancer (40)
Parkinson's disease (85)
Partnered (2)
Patents (65)
Patient recruitment (47)
Peanut (17)
People (9558)
Pharmaceutical (8)
Phase I (6158)
Phase II (10626)
Phase III (10256)
Pipeline (604)
Policy (15)
Postmarket research (1155)
Preclinical (2696)
Press Release (12)
Prostate cancer (62)
Psychedelics (4)
Radiopharmaceuticals (68)
Rare diseases (152)
Real estate (717)
Recruiting (4)
Regulatory (5471)
Reports (7)
Research institute (527)
Resumes & cover letters (15)
Rett syndrome (4)
RSV (16)
Schizophrenia (33)
Series A (52)
Series B (39)
Service/supplier (2)
Sickle cell disease (23)
Special edition (2)
Spinal muscular atrophy (32)
Sponsored (6)
Startups (510)
Stomach cancer (10)
Supply chain (29)
Tariffs (6)
The Weekly (8)
Vaccines (161)
Venture capitalists (11)
Weight loss (41)
Women's health (9)
Date
Today (96)
Last 7 days (489)
Last 30 days (1397)
Last 365 days (14637)
2025 (5579)
2024 (13308)
2023 (13162)
2022 (15431)
2021 (16148)
2020 (15147)
2019 (12249)
2018 (9157)
2017 (8497)
2016 (8058)
2015 (10106)
2014 (7426)
2013 (5404)
2012 (5995)
2011 (6478)
2010 (5724)
Location
Africa (88)
Alabama (15)
Alaska (1)
Arizona (48)
Arkansas (4)
Asia (9012)
Australia (1438)
California (3055)
Canada (742)
China (255)
Colorado (137)
Connecticut (163)
Delaware (100)
Europe (23612)
Florida (364)
Georgia (87)
Idaho (9)
Illinois (238)
India (10)
Indiana (123)
Iowa (4)
Japan (96)
Kansas (13)
Kentucky (5)
Louisiana (1)
Maine (22)
Maryland (356)
Massachusetts (2362)
Michigan (71)
Minnesota (151)
Missouri (54)
Montana (2)
Nebraska (2)
Nevada (21)
New Hampshire (16)
New Jersey (906)
New Mexico (6)
New York (816)
North Carolina (355)
North Dakota (2)
Northern California (1299)
Ohio (72)
Oklahoma (4)
Oregon (9)
Pennsylvania (533)
Puerto Rico (3)
Rhode Island (8)
South America (163)
South Carolina (2)
Southern California (1166)
Tennessee (49)
Texas (413)
United States (10765)
Utah (82)
Virginia (63)
Washington D.C. (20)
Washington State (278)
West Virginia (1)
Wisconsin (43)
184,983 Results for "amorchem l p".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
EveryONE Medicines Announces Appointment of Michelle L. Mellion, MD, as Chief Medical Officer
April 16, 2025
·
4 min read
Press Releases
Bruker Introduces nVista 2P Miniature Microscope
April 17, 2025
·
3 min read
Pharm Country
Purdue Pharma L.P. Awards Grant for Investigator-initiated Research to Examine Opioid Overdose Reversal Using Nalmefene HCl Injection
Purdue Pharma L.P. (“Purdue”) announced today that the Company has awarded an investigator-initiated research (IIR) grant to a team of researchers at The University of New Mexico (UNM) for the evaluation of nalmefene hydrochloride (HCl) injection 2mg/2mL (1mg/1mL) in the emergency department setting.
March 27, 2024
·
7 min read
Policy
Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. Enter Binding Settlement Agreement and Mutual Release
Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. have entered into a binding settlement agreement and mutual release settling ongoing litigation.
December 1, 2023
·
6 min read
Business
Daxor Corporation Appoints John L. Jefferies, M.D. as Chief Medical Officer
Daxor Corporation today announces the appointment of Dr. John L. Jefferies, M.D., M.B.A., M.P.H., F.A.C.C., F.A.H.A., F.A.A.P., F.H.F.S.A., F.E.S.C., F.R.C.P.E., as Chief Medical Officer.
June 5, 2024
·
4 min read
Press Releases
Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma
February 19, 2025
·
9 min read
Press Releases
Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody™ ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025
May 1, 2025
·
7 min read
Press Releases
Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors
March 28, 2025
·
9 min read
Press Releases
WuXi Biologics Completes First Commercial PPQ Campaign at 15,000L Production Line in Hangzhou Site
April 18, 2025
·
3 min read
Press Releases
PD-L1 Measured by Blood Test Reveals Important Clinical Information
March 12, 2025
·
2 min read
1 of 18,499
Next
